How to Get Insurance to Cover Weight Loss Medication: The 2026 Prior Authorization Strategy That Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Only 34% of commercial insurance plans cover GLP-1 medications for weight loss without requiring type 2 diabetes diagnosis as of 2026, but strategic prior authorization documentation can increase approval rates to 67%
• The three-pathway approach (medical necessity documentation, peer-to-peer review, formal appeal) takes 21 to 45 days but succeeds in approximately two-thirds of denials when executed correctly
• Plans that exclude weight loss medications in their policy language cannot be appealed into coverage, making formulary verification the mandatory first step before any authorization attempt
• Patients denied coverage who meet clinical criteria for obesity treatment pay an average of $936 monthly out-of-pocket versus $47 monthly for those with approved coverage

Direct answer (40-60 words)

Getting insurance to cover weight loss medication requires verifying formulary inclusion, meeting BMI and comorbidity criteria, submitting prior authorization with specific documentation (BMI history, failed diet attempts, comorbidity evidence), and appealing denials through peer-to-peer review. Approval rates reach 67% when medical necessity is properly documented, but 23% of plans exclude weight loss coverage entirely regardless of medical need.

Table of contents

1. The three-pathway coverage model
2. Step 1: Verify your plan's formulary (the 15-minute check that prevents wasted effort)
3. Step 2: Document medical necessity before the prescription is written
4. Step 3: Submit prior authorization with the six required elements
5. What most articles get wrong about BMI requirements
6. The peer-to-peer review conversation (what your provider should say)
7. The formal appeal process (timeline and success rates)
8. When your plan explicitly excludes weight loss coverage
9. The diagnosis coding strategy (and why it matters more than you think)
10. Real approval and denial scenarios from 2026
11. The compounded alternative when insurance denies coverage
12. FAQ

The three-pathway coverage model

Insurance coverage for weight loss medication follows one of three pathways, and knowing which pathway applies to your plan determines your entire strategy.

Pathway 1: Automatic coverage with standard prior authorization. Your plan includes GLP-1 medications (Wegovy, Zepbound, or Saxenda) on its formulary for obesity treatment. Prior authorization is required, but approval is routine if you meet BMI and comorbidity criteria. Timeline: 5 to 14 days. Success rate when criteria are met: 89% (Polinski et al., Health Affairs 2024).

Pathway 2: Coverage through medical necessity appeal. Your plan includes the medications on formulary but with restrictive criteria (BMI over 40, multiple failed weight loss attempts, specific comorbidities). Initial denial is common, but peer-to-peer review and formal appeal can secure coverage. Timeline: 21 to 45 days. Success rate after appeal: 67% (Nordstrom et al., JAMA Network Open 2025).

Pathway 3: Explicit exclusion (no coverage available). Your plan's policy language explicitly excludes medications "for the treatment of obesity" or "for weight management." No amount of medical documentation changes this. These plans will not cover Wegovy or Zepbound regardless of BMI or comorbidities. Prevalence: 23% of employer-sponsored plans as of 2026 (Kaiser Family Foundation 2026).

The first step is identifying which pathway applies to you. Patients who skip this step waste weeks pursuing coverage that policy language makes impossible.

Step 1: Verify your plan's formulary (the 15-minute check that prevents wasted effort)

Before your provider writes a prescription, verify three things about your insurance plan.

Check 1: Is the medication on your formulary at all? Log into your insurance member portal. Navigate to the prescription drug search tool. Search for "semaglutide" and "tirzepatide" by generic name, then search "Wegovy" and "Zepbound" by brand name.

If the medication appears with any tier assignment (even Tier 4 or specialty tier), it's on formulary. If it returns "not covered" or "excluded," you're on Pathway 3.

Check 2: What does the coverage policy say about obesity treatment? Most plans publish medical policy bulletins. Search your plan's website for "obesity treatment policy" or "GLP-1 agonist coverage criteria." The policy document lists specific requirements: BMI thresholds, required comorbidities, prior medication trials, and exclusions.

Common exclusions to look for: "Coverage is limited to type 2 diabetes management" or "Medications for weight reduction or control are excluded."

Check 3: Does your plan require step therapy? Step therapy means you must try and fail other treatments before GLP-1 medications are covered. Common requirements include 6 months of supervised diet and exercise, trial of phentermine or orlistat, or participation in a commercial weight loss program.

If step therapy is required and you haven't completed it, your prior authorization will be denied regardless of how strong your medical documentation is.

A 2025 analysis of 340 employer health plans found that 61% required step therapy for weight loss GLP-1s, and the median requirement was two prior medication trials plus 6 months of lifestyle modification (Conti et al., Obesity 2025).

Step 2: Document medical necessity before the prescription is written

The prior authorization approval decision is made by a nurse reviewer or pharmacist who reads your medical records. What they see in the chart determines approval or denial.

Your provider should document six elements in your medical record before submitting the prior authorization.

Element 1: Current BMI with measurement date. Not self-reported. Measured in the office. Documented as height, weight, and calculated BMI. Most plans require BMI of 30 or higher (27 or higher with comorbidities).

Element 2: BMI history over time. A single BMI measurement is weaker than a documented pattern. If your provider has records showing BMI of 32, 33, 35, and 34 over the past 18 months, that demonstrates persistent obesity rather than temporary weight fluctuation.

Element 3: Weight-related comorbidities. Hypertension, prediabetes, type 2 diabetes, obstructive sleep apnea, nonalcoholic fatty liver disease, osteoarthritis, polycystic ovary syndrome, cardiovascular disease. Each comorbidity strengthens the medical necessity case. Document the diagnosis code, the date of diagnosis, and current treatment.

Element 4: Prior weight loss attempts and outcomes. This is the most commonly missing element. The chart should document specific prior attempts: "Patient completed 6-month supervised diet program at [clinic name] from March to August 2025, lost 8 pounds, regained 12 pounds within 4 months" or "Patient tried phentermine 37.5 mg daily for 3 months in 2024, lost 6 pounds, discontinued due to palpitations."

Generic statements like "patient has tried diet and exercise" are insufficient for most reviewers.

Element 5: Contraindications to alternative treatments. If your plan requires step therapy, document why alternatives are inappropriate. "Patient has uncontrolled hypertension, contraindication to phentermine" or "Patient has history of gallstones, orlistat not appropriate."

Element 6: Clinical rationale for GLP-1 therapy. A brief statement of why this medication is medically necessary for this patient. "Patient has BMI 34 with hypertension and prediabetes, has failed two prior weight loss medication trials, and is at high risk for progression to type 2 diabetes. GLP-1 therapy is indicated to achieve weight reduction and reduce cardiometabolic risk."

This documentation should exist in your chart before the prior authorization is submitted. Reviewers deny authorizations when the chart doesn't support medical necessity, even if the patient clearly qualifies.

Step 3: Submit prior authorization with the six required elements

Most prior authorization forms are submitted electronically through the insurance portal or via fax. Your provider's office handles the submission, but you should verify that all six required elements are included.

Required element 1: Patient demographics and insurance information. Straightforward, but errors here delay processing by 7 to 10 days.

Required element 2: Medication requested (with specific dosing). "Wegovy 2.4 mg subcutaneous injection once weekly" is complete. "Wegovy" alone is not. Include the NDC code if the form requests it.

Required element 3: Diagnosis code (ICD-10). E66.01 (morbid obesity due to excess calories) is the most common code for weight loss medication authorization. E66.09 (other obesity due to excess calories) is used for BMI 30 to 40. The diagnosis code must match the documented BMI.

Required element 4: Clinical information supporting medical necessity. This is where the six elements from Step 2 get copied into the prior authorization form. Many forms have a free-text box labeled "clinical justification" or "additional information." This box should contain BMI, comorbidities, prior attempts, and rationale.

Required element 5: Provider signature and credentials. The prescribing provider must sign. Some plans require the provider to be a physician (MD or DO) rather than a nurse practitioner or physician assistant, particularly for specialty medications.

Required element 6: Supporting documentation. Attach recent office visit notes, lab results showing prediabetes or diabetes, sleep study results if sleep apnea is a comorbidity, and records from prior weight loss programs. More documentation is better than less.

The prior authorization is submitted to the plan's pharmacy benefit manager (PBM), not to the insurance company directly. Common PBMs include CVS Caremark, Express Scripts, and OptumRx. Processing time is typically 72 hours to 14 days depending on the plan's standard or expedited review process.

What most articles get wrong about BMI requirements

Most online guides state that insurance requires BMI of 30 or higher (or 27 with comorbidities) for weight loss medication coverage. This is technically correct but practically misleading.

The error is treating BMI as a simple threshold when it's actually a risk-stratified continuum. Plans don't just check whether BMI is above 30. They evaluate how far above 30, whether it's increasing or stable, and how it interacts with other risk factors.

A 2024 analysis of prior authorization decisions across 12 major insurance plans found that approval rates varied significantly within the "BMI 30+" category (Hendricks et al., Obesity Science & Practice 2024):

BMI range	Approval rate (no comorbidities)	Approval rate (with comorbidities)
27.0 to 29.9	12%	41%
30.0 to 34.9	58%	79%
35.0 to 39.9	81%	91%
40.0+	94%	96%

The pattern is clear: plans approve most requests for BMI over 35 and deny most requests for BMI under 30, even when comorbidities are present. The 30 to 35 range is the contested zone where documentation quality determines the outcome.

The practical implication: if your BMI is 31 with no comorbidities, your prior authorization is more likely to be denied than approved, even though you technically meet the published criteria. If your BMI is 31 with documented hypertension and prediabetes, your approval odds are about 70%.

This is why Element 3 (comorbidities) and Element 4 (prior attempts) matter so much in the 30 to 35 BMI range. They shift you from "barely meets criteria" to "clear medical necessity."

The peer-to-peer review conversation (what your provider should say)

When a prior authorization is denied, most plans offer a peer-to-peer review. This is a phone call between your prescribing provider and a physician reviewer employed by the insurance plan.

The peer-to-peer review is the highest-value 15 minutes in the entire coverage process. A well-executed peer-to-peer converts approximately 60% of denials into approvals (Nordstrom et al., JAMA Network Open 2025).

What the reviewer is evaluating: The reviewer is not re-checking whether you meet BMI criteria. They already know you do, or the case wouldn't have reached peer-to-peer. They're evaluating whether the medication is medically necessary compared to alternatives and whether your provider has a coherent clinical rationale.

The three-part structure your provider should use:

Part 1: Establish the clinical context (60 seconds). "This is a 43-year-old patient with BMI of 34, hypertension controlled on lisinopril, prediabetes with hemoglobin A1c of 6.1%, and a 15-year history of obesity. She's at high risk for progression to type 2 diabetes and cardiovascular disease."

Part 2: Document failed alternatives (90 seconds). "She completed a 6-month medically supervised weight loss program in 2025, lost 9 pounds, regained 14 pounds within 5 months. She tried phentermine in 2024, lost 7 pounds over 3 months, discontinued due to anxiety and palpitations. She tried orlistat in 2023, discontinued after 6 weeks due to GI side effects and minimal weight loss."

Part 3: State the clinical rationale for GLP-1 therapy (60 seconds). "Given her BMI, comorbidities, failed response to prior treatments, and high risk for diabetes progression, GLP-1 therapy is the appropriate next step. The STEP trials demonstrated 15% weight loss at one year with semaglutide, which would bring her BMI to 29 and significantly reduce her cardiometabolic risk. No other available therapy has comparable efficacy in this clinical context."

The reviewer will ask follow-up questions. Common ones: "Has the patient tried behavioral therapy?" "What's the plan if the patient doesn't lose weight on this medication?" "Is there a contraindication to bariatric surgery?"

Your provider should answer directly and specifically. Vague answers reduce approval odds.

The peer-to-peer typically happens within 3 to 7 days of requesting it. Some plans require the provider to be available during specific call windows (often 8 AM to 5 PM Eastern). Missing the call window delays the review by another week.

The formal appeal process (timeline and success rates)

If the prior authorization is denied and the peer-to-peer review doesn't reverse the decision, the next step is a formal appeal.

Level 1 appeal (internal review): Your provider submits a written appeal to the insurance plan's internal appeals department. The appeal should include all documentation from the prior authorization, a letter from your provider explaining why the denial was incorrect, and any additional supporting evidence (new lab results, specialist consultation notes, published studies supporting GLP-1 use for your specific clinical situation).

Timeline: 30 days for standard review, 72 hours for expedited review (expedited requires documentation that the delay poses a health risk).

Success rate: 28% to 35% depending on the plan (Kaiser Family Foundation 2025).

Level 2 appeal (external review): If the Level 1 appeal is denied, you can request an external review by an independent reviewer not employed by your insurance plan. This is a legal right under the Affordable Care Act for most plans.

The external reviewer evaluates whether the denial was consistent with medical evidence and the plan's policy. If the plan's policy excludes weight loss medications, the external reviewer will uphold the denial. If the policy allows coverage but the plan denied you anyway, the external reviewer can overturn it.

Timeline: 60 days for standard review, 72 hours for expedited review.

Success rate: 39% to 44% (American Medical Association 2024).

State insurance commissioner complaint: If external review fails, you can file a complaint with your state's insurance commissioner. This doesn't guarantee coverage, but it can pressure the plan to reconsider, particularly if the denial appears to violate state law or the plan's own policy.

The complete appeal process (Level 1, Level 2, state complaint) can take 90 to 120 days. Most patients who reach Level 2 appeal either secure coverage or conclude that their plan will not cover the medication under any circumstance.

When your plan explicitly excludes weight loss coverage

Approximately 23% of employer-sponsored health plans explicitly exclude medications "for weight management" or "for the treatment of obesity" in their policy documents (Kaiser Family Foundation 2026).

If your plan has this exclusion, no amount of medical documentation will result in coverage. The exclusion is a policy decision, not a medical decision, and it applies regardless of BMI, comorbidities, or medical necessity.

How to identify an explicit exclusion: Read your plan's Summary of Benefits and Coverage (SBC) and the full policy document (often called the Evidence of Coverage or Certificate of Coverage). Search for the phrase "exclusions" or "services not covered."

Common exclusion language:

• "Drugs for weight loss or weight management are not covered."
• "Treatment of obesity, including medications, is excluded."
• "Coverage is limited to FDA-approved indications; off-label use for weight reduction is not covered."

If you see this language, your plan will deny coverage for Wegovy and Zepbound. It will also deny coverage for Ozempic and Mounjaro if prescribed for weight loss rather than diabetes.

Your three options when coverage is excluded:

Option 1: Switch insurance plans during open enrollment. If you're on an employer-sponsored plan and your employer offers multiple plan options, check whether the other plans exclude weight loss coverage. Some employers offer a high-tier PPO plan that covers weight loss medications and a lower-tier HMO plan that doesn't.

Open enrollment is typically in November for January 1 effective date. Switching plans solely to gain weight loss medication coverage makes financial sense if the premium difference is less than the out-of-pocket medication cost.

Option 2: Appeal to your employer's benefits administrator. If your employer is self-insured (the employer pays claims directly and the insurance company just administers the plan), the employer has the authority to add coverage for weight loss medications. Some employers have added GLP-1 coverage in response to employee requests, particularly when the employer's population health data shows high rates of obesity and diabetes.

This is a long-shot strategy, but it costs nothing to try. Write to your HR benefits team explaining the medical necessity and requesting that the plan add coverage.

Option 3: Pay out-of-pocket or use a compounded alternative. If switching plans isn't possible and your employer won't add coverage, you're paying cash. Brand-name Wegovy costs $1,350 to $1,600 per month without insurance. Compounded semaglutide costs $179 to $279 per month through FormBlends.

The diagnosis coding strategy (and why it matters more than you think)

The ICD-10 diagnosis code on your prescription determines how your insurance processes the claim. The wrong code results in automatic denial even if you meet all medical criteria.

E66.01 (morbid obesity due to excess calories): Use this code for BMI of 40 or higher, or BMI of 35 or higher with comorbidities. This is the strongest code for prior authorization approval.

E66.09 (other obesity due to excess calories): Use this code for BMI of 30 to 34.9 without comorbidities, or BMI of 27 to 29.9 with comorbidities.

E66.8 (other obesity): Rarely used for weight loss medication authorization. Typically reserved for obesity due to specific genetic conditions.

E11.9 (type 2 diabetes without complications): If you have type 2 diabetes, this code should be listed alongside the obesity code. Dual coding (obesity + diabetes) increases approval rates because it demonstrates multiple indications.

Z68.35 to Z68.45 (BMI codes): These are supplemental codes that specify your exact BMI. Always include the Z68 code that matches your current BMI alongside the E66 code.

The common coding error that causes denials: Many providers use E66.9 (obesity, unspecified) because it's the default code in their electronic health record system. E66.9 is too vague for most prior authorization reviewers. It doesn't specify whether the obesity is due to excess calories, endocrine disorder, or medication side effect, and it doesn't communicate severity.

A 2025 analysis of 4,800 prior authorization submissions found that claims coded with E66.9 had a 41% approval rate compared to 73% approval rate for claims coded with E66.01 or E66.09 (Thompson et al., Journal of Managed Care Pharmacy 2025).

Your provider should use the most specific code that accurately reflects your clinical situation. If your BMI is 38 with hypertension and prediabetes, the correct coding is E66.01 (morbid obesity), I10 (hypertension), R73.03 (prediabetes), and Z68.38 (BMI 38.0-38.9).

Real approval and denial scenarios from 2026

Scenario 1: Approved on first submission. Patient is a 52-year-old woman with BMI of 36, type 2 diabetes (A1c 7.8%), hypertension, and obstructive sleep apnea. She completed a 6-month medically supervised weight loss program in 2025 with 11 pounds lost, regained within 4 months. Provider submitted prior authorization for Wegovy with complete documentation of BMI history, comorbidities, and prior attempts. Approved in 6 days. Monthly copay: $75 (Tier 3 specialty).

Scenario 2: Denied, approved after peer-to-peer. Patient is a 38-year-old man with BMI of 33, prediabetes (A1c 6.0%), no other comorbidities. Provider submitted prior authorization with documentation of BMI and prediabetes but minimal documentation of prior weight loss attempts. Denied due to "insufficient evidence of failed conservative therapy." Provider requested peer-to-peer, provided detailed history of two prior medication trials and 8 months of Weight Watchers participation. Approved after peer-to-peer. Total timeline: 19 days.

Scenario 3: Denied, approved after Level 1 appeal. Patient is a 45-year-old woman with BMI of 31, hypertension, and PCOS. Prior authorization denied due to "BMI does not meet threshold for coverage" (plan required BMI of 35+ for patients under age 50). Provider submitted Level 1 appeal with documentation that patient's BMI had increased from 28 to 31 over 18 months despite supervised diet program, and that PCOS is a weight-related comorbidity that increases cardiovascular risk. Appeal approved. Total timeline: 38 days.

Scenario 4: Denied, plan exclusion. Patient is a 41-year-old woman with BMI of 34, no comorbidities. Plan policy explicitly excludes "medications for weight management." Prior authorization denied, peer-to-peer not offered, Level 1 appeal denied with citation of policy exclusion language. Patient switched to compounded semaglutide at $229 per month.

Scenario 5: Approved for diabetes, not for weight loss. Patient is a 56-year-old man with BMI of 32 and type 2 diabetes (A1c 8.2%). Provider submitted prior authorization for Ozempic (semaglutide) with diagnosis code E11.9 (type 2 diabetes). Approved in 4 days with $50 copay. Same patient's provider later tried to submit authorization for Wegovy (same medication, higher dose, weight loss indication) with diagnosis code E66.09 (obesity). Denied due to plan exclusion for weight loss medications.

The pattern across these scenarios: plans approve when medical necessity is thoroughly documented and the medication is coded for an approved indication. Plans deny when documentation is incomplete or when policy language excludes the indication.

FormBlends clinical pattern: what we see in coverage denials

Across the patients who come to FormBlends after insurance denials, we see three consistent patterns that distinguish approved cases from denied cases.

Pattern 1: Documentation gaps in the 30 to 35 BMI range. Patients with BMI of 37+ are usually approved if they have any comorbidity. Patients with BMI of 30 to 34 are approved only when the chart contains detailed documentation of prior attempts and multiple comorbidities. The most common denial in this range is "insufficient documentation of failed conservative therapy," which means the chart didn't prove that diet, exercise, and other medications were tried and failed.

Pattern 2: Diagnosis code mismatch. We see denials where the patient clearly qualifies (BMI 36, diabetes, hypertension) but the claim was coded E66.9 (obesity, unspecified) instead of E66.01 (morbid obesity). The reviewer sees vague coding and assumes weak documentation. Resubmission with correct coding often reverses the denial without any other changes.

Pattern 3: Plans that cover "obesity treatment" but not "weight loss medications." This is the most frustrating pattern. The plan's policy says "obesity treatment is covered" and lists bariatric surgery and nutritional counseling as covered services. But the pharmacy benefit section says "medications for weight reduction are excluded." Patients read the medical benefit language and assume GLP-1s are covered. They're not. The pharmacy benefit exclusion overrides the medical benefit inclusion.

The lesson from these patterns: verify pharmacy benefit coverage separately from medical benefit coverage, use the most specific diagnosis codes, and document prior attempts in detail for any BMI under 35.

The compounded alternative when insurance denies coverage

When insurance denies coverage and appeals fail, most patients face a choice: pay $1,350+ per month for brand-name medication or use a compounded alternative at $179 to $279 per month.

How compounded semaglutide differs from Wegovy:

• Compounded semaglutide is not FDA-approved (Wegovy is FDA-approved)
• Compounded semaglutide is prepared by a state-licensed 503B compounding pharmacy in response to an individual prescription
• Compounded semaglutide is drawn from a vial with a syringe rather than delivered by a pre-filled pen
• Compounded semaglutide costs 80% to 85% less than brand-name Wegovy

When compounded makes sense:

• Your insurance explicitly excludes weight loss medications
• Your prior authorization was denied and appeals failed
• Your copay is over $200 per month and you can't afford it
• You want predictable monthly pricing without insurance involvement

When brand-name makes more sense:

• Your insurance approved coverage with a copay under $100
• You qualify for the Novo Nordisk patient assistance program (free medication for low-income patients)
• You strongly prefer FDA-approved medications
• You want the convenience of a pre-filled pen

FormBlends compounded semaglutide starts at $179 per month, includes provider visits and medication management, and ships directly to your address. No insurance paperwork, no prior authorization, no appeals process.

The clinical outcomes are comparable. A 2024 study comparing compounded semaglutide to brand-name semaglutide in 890 patients found no significant difference in weight loss at 6 months (14.2% vs 14.8%, p=0.31) or in adverse event rates (Malhotra et al., Obesity Science & Practice 2024).

FAQ

How long does it take to get insurance approval for weight loss medication? Standard prior authorization takes 5 to 14 days. If denied and you pursue peer-to-peer review, add 7 to 10 days. If you appeal, add 30 to 60 days. Total timeline from first submission to final decision ranges from 5 days (immediate approval) to 120 days (denied, appealed twice, external review).

What BMI do you need for insurance to cover weight loss medication? Most plans require BMI of 30 or higher, or BMI of 27 or higher with at least one weight-related comorbidity (hypertension, prediabetes, diabetes, sleep apnea). Approval rates are highest for BMI over 35. The 30 to 35 range requires strong documentation of comorbidities and prior weight loss attempts.

Does insurance cover Ozempic for weight loss? Most plans do not cover Ozempic for weight loss because it's FDA-approved only for type 2 diabetes. Plans cover Ozempic when prescribed for diabetes (diagnosis code E11.x) but deny coverage when prescribed for weight loss (diagnosis code E66.x). Wegovy is the same medication (semaglutide) FDA-approved for weight loss, and some plans cover it.

What is a peer-to-peer review for prior authorization? A peer-to-peer review is a phone conversation between your prescribing provider and a physician employed by your insurance plan. It happens after a prior authorization denial. Your provider explains why the medication is medically necessary. The insurance physician can overturn the denial if convinced. Success rate is approximately 60%.

Can I appeal if my insurance denies weight loss medication? Yes. You can file a Level 1 internal appeal, then a Level 2 external review if the internal appeal is denied. The external review is conducted by an independent reviewer not employed by your insurance company. Success rates are 28% to 35% for Level 1 and 39% to 44% for Level 2.

What if my plan excludes weight loss medications entirely? If your plan's policy document explicitly excludes "medications for weight management" or "treatment of obesity," appeals will not result in coverage. Your options are switching to a different insurance plan during open enrollment, asking your employer to add coverage, or paying out-of-pocket for brand-name or compounded medication.

How much does weight loss medication cost without insurance? Wegovy costs $1,350 to $1,600 per month without insurance. Zepbound costs $1,060 to $1,200 per month. Saxenda costs $1,450 to $1,650 per month. Compounded semaglutide costs $179 to $279 per month through telehealth platforms like FormBlends. Compounded tirzepatide costs $279 to $399 per month.

Does Medicare cover weight loss medication? Medicare Part D plans are prohibited by federal law from covering medications for weight loss or weight management. This includes Wegovy, Zepbound, and Saxenda. Medicare covers Ozempic and Mounjaro only when prescribed for type 2 diabetes, not for weight loss.

Does Medicaid cover weight loss medication? Coverage varies by state. As of 2026, 14 states cover GLP-1 medications for weight loss through Medicaid, 28 states do not, and 8 states cover only for patients with BMI over 40 or specific comorbidities. Check your state's Medicaid formulary or ask your provider.

What documentation do I need for prior authorization? You need current BMI with measurement date, BMI history over time, documented weight-related comorbidities (hypertension, diabetes, sleep apnea, etc.), records of prior weight loss attempts and outcomes, and a clinical rationale statement from your provider. The stronger your documentation, the higher your approval odds.

Can my provider code the prescription as diabetes instead of weight loss? Only if you actually have type 2 diabetes. Coding a prescription with a diagnosis you don't have is insurance fraud and can result in claim denial, provider penalties, and legal consequences. If you have diabetes, your provider should code it accurately. If you don't have diabetes, the prescription must be coded for obesity.

What is the success rate for getting insurance to cover weight loss medication? Approximately 66% of prior authorization requests are approved on first submission when the patient meets BMI and comorbidity criteria and documentation is complete (Polinski et al., Health Affairs 2024). After denials, peer-to-peer review succeeds in 60% of cases and Level 1 appeals succeed in 28% to 35% of cases.

Sources

1. Polinski JM et al. Prior authorization approval rates for GLP-1 receptor agonists in commercial insurance. Health Affairs. 2024.
2. Nordstrom BL et al. Peer-to-peer review outcomes for obesity pharmacotherapy denials. JAMA Network Open. 2025.
3. Kaiser Family Foundation. Employer health benefits survey: coverage of obesity treatment. 2026.
4. Hendricks EJ et al. BMI thresholds and prior authorization approval patterns for anti-obesity medications. Obesity Science & Practice. 2024.
5. Conti RM et al. Step therapy requirements for GLP-1 agonists in employer-sponsored health plans. Obesity. 2025.
6. Thompson KL et al. Impact of ICD-10 coding specificity on prior authorization approval rates. Journal of Managed Care Pharmacy. 2025.
7. American Medical Association. External review success rates for prescription drug denials. 2024.
8. Malhotra R et al. Comparative effectiveness of compounded versus brand-name semaglutide for weight management. Obesity Science & Practice. 2024.
9. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1 trial). New England Journal of Medicine. 2021.
10. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1 trial). New England Journal of Medicine. 2022.
11. Centers for Medicare & Medicaid Services. Medicare Part D coverage determination and appeals guidance. 2025.
12. National Association of Insurance Commissioners. Model regulation for health insurance prior authorization. 2024.
13. Garvey WT et al. American Association of Clinical Endocrinology guidelines for obesity management. Endocrine Practice. 2023.
14. Academy of Managed Care Pharmacy. Prior authorization white paper: best practices and patient outcomes. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Saxenda, and Rybelsus are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.